REmission in Membranous Nephropathy International Trial (REMIT)
Status:
Not yet recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
REMIT is an investigator-initiated, international, multi-centre, prospective, randomised,
open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous
Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada,
Asia, Europe, United Kingdom, and other countries. Participants will be randomised to receive
either corticosteroid and cyclophosphamide or obinutuzumab. The primary outcome is a ranked,
composite measure based on (a) efficacy, defined as either complete or partial remission of
PMN, (b) number of adverse events, and (c) quality of life.